Simnova (先博生物) is a Shanghai-based clinical-stage cell therapy company incubated by Simcere (先声药业) and operating independently since 2021, focused on off-the-shelf (universal) CAR-NK therapies, in vivo CAR-T, and multi-target solid-tumor CAR-T platforms. Its lead candidate SNC103, an anti-CD19 universal CAR-NK, reported a 100% SRI-4 response rate in a Phase 1 trial in moderate-to-severe systemic lupus erythematosus, while its in vivo CAR-T candidate SNC116 has entered clinical study at the Cancer Hospital of the Chinese Academy of Medical Sciences. The company has also partnered with ORNA Therapeutics (later acquired by Eli Lilly) on LNP delivery and circular RNA technology.
1
Round
1
Industry
5
Tags
Aug 31, 2026
Latest raise
Funding activity · 1 round
Aug 31, 2026
CNY 400M
Series B
Led by Pudong Chuangtou
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
